Projections of human papillomavirus (HPV) vaccination impact on non-cervical cancer outcomes among women in 117 low-income and middle-income countries: a modeling study

IntroductionHuman papillomavirus (HPV) is a leading cause of both cervical and non-cervical cancers, including anal, oropharyngeal, vaginal, and vulvar cancers. While most HPV vaccination impact assessments have focused on preventing cervical cancer among women, the broader benefits of vaccination against other HPV-attributable cancers in low- and middle-income countries (LMICs) remain less explored. MethodsWe used a static cohort model to assess the potential health impact of bivalent HPV vaccination on HPV-attributable female non-cervical cancers in 117 LMICs from 2030 to 2100. The model incorporated country-specific data on cancer mortality, HPV type distribution, demographic projections, and vaccine coverage. Sensitivity analyses were performed to account for uncertainties in cancer incidence and mortality, HPV type distribution, and cancer stage distribution. ResultsOur projections suggest that HPV vaccination could contribute to prevention of approximately 0.59 million cases of anal, 0.88 million oropharyngeal, 1.27 million vaginal, and 2.18 million vulvar cancers over the analytic period. In total, 3.0 million deaths from these non-cervical cancers could be averted by 2100. The African Region is expected to see the largest relative reductions in both cases and deaths, while the European region showed the smallest gains. By the end of the century, 58 countries are projected to reach at least a 25% reduction in anal cancer mortality, compared to just 25 countries for oropharyngeal cancer. These findings reflect substantial regional disparities in both burden and vaccination impact. ConclusionHPV vaccination holds considerable promise in reducing the burden of non-cervical cancers among women in LMICs, especially in regions with high incidence and limited access to care. Recognizing and harnessing these broader benefits can strengthen the public health case for scaling up vaccine access, implementing region-specific strategies, and investing in equitable healthcare systems to decrease global disparities. KEY MESSAGESO_ST_ABSWhat is Already Known About This Topic?C_ST_ABSO_LIHealth-impact modelling has been used to project the impact of human papillomavirus (HPV) vaccination on prevention of cervical cancer. C_LIO_LIHPV is a leading cause of non-cervical cancers, including anal, oropharyngeal, vaginal, and vulvar cancers. C_LI What Does This Study Add?O_LIThis study estimated the impact of HPV vaccination on non-cervical female cancers, projecting the largest reductions in the African region. C_LI How Might This Study Affect Research, Practice, or Policy?O_LIIn order to improve coverage of HPV vaccination programs, it will be important to estimate additional cancer prevention benefits that can mitigate disease burden in low- and middle-income countries. C_LI